# 3E Extension Study

> **NCT01834508** · PHASE4 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 600 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks

## Key facts

- **NCT ID:** NCT01834508
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2016-06
- **Final completion:** 2016-12
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2014-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01834508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01834508, "3E Extension Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01834508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*